Annual report pursuant to Section 13 and 15(d)

Revenues

v3.22.2.2
Revenues
 12 Months Ended
Aug. 31, 2022
Revenues  
Revenues

13. Revenues

 

 

 

August 31

2022

$

 

 

August 31

2021

$

 

B2B sales

 

 

 113,438

 

 

 

 383,179

 

Licensing Revenue

 

 

 54,560

 

 

 

 334,974

 

Research & Development

 

 

 54,800

 

 

 

 -

 

Other Revenue

 

 

 32,599

 

 

 

 4,585

 

 

 

 

 255,397

 

 

 

 722,738

 

 

The Company recognized B2B product revenues of $113,438 (2021 - $383,179) that relate to sales of our intermediate products for use by four B2B customers in their products. Licensing revenue consist of IP licensing fees for transfer of the DehydraTECH technology in line with definitive agreements and also includes royalty fees. The Company recognized $54,560 (2021 - $334,974) in licensing revenue during the year.